{
    "N/R/U": null,
    "Applicant": "Boehringer Ingelheim Pharmaceuticals, Inc.",
    "BLA Number": "761058",
    "Proprietary Name": "Cyltezo",
    "Proper Name": "adalimumab-adbm",
    "BLA Type": "351(k) Interchangeable",
    "Strength": "40MG/0.8ML",
    "Dosage Form": "Injection ",
    "Route of Administration": "Subcutaneous",
    "Product Presentation": "Autoinjector",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "May 18, 2023",
    "Ref. Product Proper Name": "adalimumab",
    "Ref. Product Proprietary Name": "Humira",
    "Supplement Number": "16",
    "Submission Type": "Supplement",
    "License Number": "2006",
    "Product Number": "004",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": "April 15, 2023",
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": null,
    "drug": [
        {
            "name": "adalimumab-adbm",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00051"
        }
    ]
}